Media

GenSight Biologics reports positive additional data from REVERSE Phase III clinical trial of GS010 for treatment of Leber Hereditary Optic Neuropathy (LHON)

Nordic Nanovector Announces Betalutin® has been granted Fast Track designation in the US for Follicular Lymphoma

Nordic Nanovector to present preclinical data demonstrating Betalutin® reverses resistance to anti-CD20 treatment in NHL cells

Onxeo Secures $7.5 Million of Non-dilutive Capital from SWK Holdings Corporation Through Sale of Rights related to Future Beleodaq® Royalties

BioClin Therapeutics Presents FIERCE-21: Phase 1b/2 Study of Docetaxel + B-701, a Selective Inhibitor of FGFR3, in Relapsed or Refractory Metastatic Urothelial Carcinoma at the American Society of Clinical Oncology (ASCO). Chicago, IL.

Wilson Therapeutics to present data from WTX101 Phase 2 extension study at 4th Congress of the European Academy of Neurology

Nordic Nanovector Strengthens Management Team with Appointment of Maureen Deehan, PhD, as Head of Corporate Development and Strategy

Strongbridge Biopharma plc to Present at the Jefferies 2018 Global Healthcare Conference

Nordic Nanovector: Rainer Boehm, MD elected to Board of Directors